IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Détails bibliographiques
Publié dans:	Clinical immunology (Orlando, Fla.). - 1999. - 174(2017) vom: 01. Jan., Seite 63-72
Auteur principal:	Balak, Deepak M W (Auteur)
Autres auteurs:	van Doorn, Martijn B A, Arbeit, Robert D, Rijneveld, Rianne, Klaassen, Erica, Sullivan, Tim, Brevard, Julie, Thio, Hok Bing, Prens, Errol P, Burggraaf, Jacobus, Rissmann, Robert
Format:	Article en ligne
Langue:	English
Publié:	2017
Accès à la collection:	Clinical immunology (Orlando, Fla.)
Sujets:	Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Drug-development Endosomal toll-like receptors Human beta-defensin-2 Immune-mediated inflammatory diseases Oligonucleotide antagonist Type 1 interferon signaling pathway plus... DEFB4A protein, human TLR7 protein, human TLR8 protein, human TLR9 protein, human Toll-Like Receptor 7 Toll-Like Receptor 8 Toll-Like Receptor 9 beta-Defensins

Accès en ligne	Volltext